Update on Parkinson Disease
- 15 April 2003
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 138 (8) , 651-658
- https://doi.org/10.7326/0003-4819-138-8-200304150-00013
Abstract
This Update reviews developments in the pathophysiology and treatment of Parkinson disease during the past several years. In the area of pathophysiology, studies have addressed the contribution of environmental factors such as caffeine and pesticides. Large-scale epidemiologic studies have also expanded the role genetic factors are thought to play. Detailed studies of kindreds with familial Parkinson disease due to alpha-synuclein and parkin have catalyzed basic science investigations into the pathologic mechanisms of the disease. These studies have led to the development of a pathophysiologic model of Parkinson disease that emphasizes abnormal protein aggregation. Studies of treatment have clarified the relative roles of l-dopa and dopamine agonists in early Parkinson disease and shown the potential for surgical interventions, particularly deep-brain stimulation, to relieve the symptoms of advanced, medically refractory disease.Keywords
This publication has 51 references indexed in Scilit:
- Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease ProgressionJAMA, 2002
- Complete Genomic Screen in Parkinson DiseaseJAMA, 2001
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000
- Oxidative Stress and Genetics in the Pathogenesis of Parkinson's DiseaseNeurobiology of Disease, 2000
- Association of Coffee and Caffeine Intake With the Risk of Parkinson DiseaseJAMA, 2000
- The α-synuclein gene is not a major risk factor in familial Parkinson diseaseneurogenetics, 1999
- The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twinsAnnals of Neurology, 1999
- Parkinson Disease in TwinsAn Etiologic StudyJAMA, 1999
- De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmosetMovement Disorders, 1998
- Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot studyAnnals of Neurology, 1996